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FDA Issues Warning About an Ingre-
dient in Cold Remedies and Diet
Drugs
The Dangers of PPA:
Phenylpropanolamine ("PPA") is a drug that has
been used widely for years in non-prescription diet pills
and cold remedies.' The drug is a central nervous system
stimulant that can increase the heart rate and blood
pressure.2 PPA works as a decongestant because it shrinks
a swollen congested nose by narrowing the blood
vessels.3 The effectiveness of PPA as a diet drug has been
questioned for years.4 A survey of the readers of Con-
sumer Reports in the mid-1990s revealed that of those who
had tried PPA-based diet pills like Acutrim andDexatrim,
fewer than five percent were satisfied.5 Evidence shows
that these drugs typically result in trivial weight loss, if
any.6
On November 7,2000, the Food and Drug Admin-
istration ("FDA") publicly warned American consumers
to stop using the many medications containing this
ingredient.7 The reason for the ban: PPA, according to a
recent study, increases the risk of stroke. In extreme cases,
a spike in a persons blood pressure, caused by taking
medication containing PPA, ruptures an artery in the
brain, causing a hemorrhagic stroke."
The FDA and the Consumer Healthcare Products
Association ("CHPA"), a group which represents drug
manufacturers, agreed five years ago to this study of
PPA's link to strokes by researchers at Yale University.9
The study was to be published in the December 21, 2000,
edition of the New England Journal of Medicine, but the
findings were so compelling they were released seven
weeks early: 18- to 49-year-old victims of hemorrhagic
strokes were two to fifteen times more likely to have
taken PPA within three days of the stroke. ° In addition,
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researchers estimate that the link between PPA and
strokes is even stronger because the study excluded
stroke victims who had died or lost their ability to
communicate." According to the study, between 200 and
500 strokes a year were linked to the ingredient and the
risk of stroke grows when the dosage exceeds 75 milli-
grams a day. 2
In addition to the risk of PPA alone, medical stud-
ies done even before 1995 have shown that combining
caffeine and PPA can be dangerous." Both PPA and
caffeine, as stimulants, cause blood pressure to rise.' 4
Those who combined the equivalent of a PPA diet pill
and three cups of coffee show blood-pressure increases
into the hypertension range.'5 As a result of this discov-
ery, ten years ago the FDA banned caffeine from PPA diet
pills.16 But, diet pills never carried a warning to alert
consumers that the combination of caffeine and diet pills
- a veritable norm for dieters - could be dangerous. 7
FDA Action Based on the Study:
Based on the FDA advisors decision to classify
PPA as unsafe, the FDA will likely ban nonprescription
PPA.18 The FDA is not bound by the decisions of its advi-
sors, but does usually follow them.'9 The process is not so
speedy, however. In order to permanently ban the drug,
the FDA must first issue a new regulation governing
over-the-counter products and seek public comment. 20
Then, the FDA must initiate separate proceedings to
remove the ingredient from prescription drugs.2' The
process could take months and the FDA issued the recent
warning to give consumers immediate notice of the risks
of PPA 2
For now, the FDA has asked drug companies to
remove PPA from the market.23 The CHPA has continued
to defend the safety of PPA when used properly, but its
member drug companies are acknowledging and acting
on the warning issued by the FDA.24Manufacturers knew
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three weeks before the warning was given, when the
FDAs advisors voted PPA unsafe, that this FDA move
was coming.2 Bayer has already agreed to reformulate its
Alka-Seltzer Plus products to exclude PPA, and Bristol-
Myers Squibb and SmithKline Beecham have both stated
that they would stop marketing PPA-containing
medications. 26 The makers of Dimetapp, Whitehall-
Robinson Healthcare, quit shipping Dimetapp containing
PPA.27 Other manufacturers of PPA-containing medica-
tions have not yet made public their plans to deal with
the warning.2 All of them are bracing for possible law-
suits alleging they marketed a product they knew to be
unsafe.29 Walgreen Co. and CVS Pharmacy began pulling
all PPA-containing medications from their shelves in
response to the FDA's warning.3? Makers of prescription
drugs containing PPA have also been asked by the FDA
to stop selling the drugs.3'
What Consumers Should Know:
PPA is found in cold medications and diet drugs.
Some of the most common medications containing PPA
(in at least one form of the medication) include Acutrim,
Dexatrim, Triaminic, Contac, Tavist-D, Propagest, Alka-
Seltzer Plus, and Robitussin.32
According to the Yale University study, the risk for
the average dieter or cold sufferer when using PPA is
very small.33 Approximately 6 billion doses of PPA are
sold each year in the U.S., while the study estimates
between 200 and 500 young lives will be saved by the
recall.34
However, the risk is greater than any benefit
gained from the use of the drug.35 While hemorrhagic
strokes are the least common type, they are most devastat-
ing. 6 They are often fatal and can leave victims severely
disabled.37 Hemorrhagic strokes are very rare in young
people.3s According to FDA estimates, of the 130 million
Americans ages 18-49, 10,400 suffer a hemorrhagic stroke
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each year.3 9 The risk of such a stroke increases with age
especially when combined with high blood pressure,
smoking, alcohol, and use of blood thinning medicines.'
Why the FDA Approved PPA in the First Place:
Prior to this most recent controversy over the risks of the
drug, PPA was permitted to be marketed as a safe and
effective over-the-counter ("OTC") appetite suppressant
by the FDA.4 ' The FDA permitted daily dosages up to
seventy-five mg. per day in any variety of dosing
regimens.42 Because of this FDA approval, one would
assume that there had been extensive well-controlled
testing of the safety and effectiveness of PPA and its
dosages.43 But, this is not the case." PPA became an ap-
proved drug because, when the FDA was given control
over OTC drugs, PPA was marketed in 75 milligrams per
day dosages, and the FDA chose to freeze the market-
place at the dosage limits that were available at that
time. There was no extensive testing. 6
What the Public Could Have Known:
The first indications of problems with use of PPA
came in the early 1980's.47 Medical journals began citing
puzzling cases of young women, with no previous health
problems, who were having strokes within a few days of
ingesting diet drugs. The FDA, itself, has record of forty-
four cases of hemorrhagic stroke among PPA users in the
past thirty years.49 And, because the FDA learns of fewer
than ten percent of the serious side effects drugs cause
each year, those numbers are only the beginning.' °
According to some attorneys representing plaintiffs in
suits relating to PPA and strokes, drug makers have
kept the public unaware of the danger by insisting on
confidentiality as a condition of settling lawsuits.5 '
These agreements have been described as agreements
which obstruct the free flow of information about the
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dangers of diet pills.5 2 Because of the number of cases
and the history of litigation over the chemical, critics of
PPA have argued for years that the FDA should have
acted long ago not just to restrict but to stop sales of diet
pills containing PPA.5 3 But, the FDA was more cautious
and insisted that there was not conclusive evidence.5 U.S.
Representative Ron Wyden from Oregon, who had been
trying to restrict the sale of PPA diet pills for years, said
in a 1994 article that the FDA was sidestepping a decision
on whether such drugs should be readily available."
Consumers or Guinea Pigs?:
According to experts, the recent FDA warning
underscores an aspect of drug testing many do not un-
derstand: The American people serve as one huge clinical
trial.56 Even when a drug has been tested by the FDA,
side effects often do not surface until thousands have
taken it for a considerable length of time. 7 During the
past three years, the FDA has banned or all-but-banned
common drugs after life-threatening side effects were
reported years after the drugs hit the market.5 8 An ex-
ample is fen-phen. Fen-phen is a combination of two
prescription weight-loss pills, fenfluramine and
phentermine, that had been taken separately since the
1960's.5 9 After 1992, dieters began taking the two
together.' In 1997, the FDA pulled fenfluramine from the
market after the combination was linked to leaky heart
valves and an often fatal lung disease, pulmonary
hypertension. 61 By the time the drug was banned, how-
ever, approximately 6 million Americans were taking the
drug.62
Keeping track of side effects is something the FDA
is trying to improve.6s Many researchers claim that the
delay in banning PPA shows the system is too weak and
takes too long.64 The program that the FDA uses to keep
track of side effects, MedWatch, relies on doctors, phar-
macists and patients to report so-called adverse incidents
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from prescription and non-prescription drugs, and even
the FDA acknowledges that unpredicted side effects
remain under-reported for years.65
In order to improve the system, the FDA has
added money and staff to its reporting system and has
asked for more resources, but Congress has been reluc-
tant to provide them.66 According to experts, the FDA
needs epidemiologists and statisticians and doctors
interested in developing a system that reports these
things in a sensible, scientific way earlier.67 In addition, it
is possible that the FDA had trouble getting research
about PPA from the drug industry, which maintains it is
safe if used properly.68 While the FDA today has record of
only forty-four cases of PPA-related strokes a in the past
thirty years, the fact that physicians, 15-year-old medical
reports and the recent study by Yale University have
chronicled dozens more makes the agency seem more
like the last to know than a protective watchdog.69
Message to Consumers:
For now, consumers should check their medicine
cabinets and the shelves of drug stores to make certain
that they are not purchasing medication containing PPA.
Though the risk of stroke is a statistically small one, it is
not one worth taking according to the most recent studies
and the judgment of the FDA. In addition, consumers
should always beware. Dr. Gary Zaloga has even gone so
far as to say that there's no such thing as a really safe
medicine. 70 His advice: If you're clearly taking medicine
chronically, you probably ought to find out more about
it. 71
If faced with the sniffles, one can, according to
experts, safely take medications with the ingredient
pseudoephedrine.72 Studies have also indicated that zinc
can help a person beat a cold. 73 Unfortunately, there are
no over-the-counter alternatives for diet pills, so dieters
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will have to consult a doctor about prescription-only
alternatives. 74
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